Evidence map›Paper›PMID 35372080›Full record

ArticleFrontiers in oncology2022

Identification of Germline Mutations in Upper Tract Urothelial Carcinoma With Suspected Lynch Syndrome.

Bao Guan, Jie Wang, Xuesong Li, Lin Lin, Dong Fang, Wenwen Kong, Chuangyu Tian, Juan Li, Kunlin Yang, Guanpeng Han and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins.International journal of urology : official journal of the Japanese Urological Association · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Bao GuanDepartment of Urology, Peking University First Hospital, Beijing, China.
Jie WangDepartment of Urology, Peking University First Hospital, Beijing, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing, China.
Lin LinDepartment of Anorectal, Yantai Baishi Anorectal Hospital, Yantai, China.
Dong FangDepartment of Urology, Peking University First Hospital, Beijing, China.
Wenwen KongKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Chuangyu TianKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Juan LiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Kunlin YangDepartment of Urology, Peking University First Hospital, Beijing, China.
Guanpeng HanDepartment of Urology, Peking University First Hospital, Beijing, China.
Yucai WuDepartment of Urology, Peking University First Hospital, Beijing, China.
Yuhui HeDepartment of Urology, Peking University First Hospital, Beijing, China.
Yiji PengDepartment of Urology, Peking University First Hospital, Beijing, China.
Yanfei YuDepartment of Urology, Peking University First Hospital, Beijing, China.
Qun HeDepartment of Urology, Peking University First Hospital, Beijing, China.
Shiming HeDepartment of Urology, Peking University First Hospital, Beijing, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, Beijing, China.
Liqun ZhouDepartment of Urology, Peking University First Hospital, Beijing, China.
Qi TangDepartment of Urology, Peking University First Hospital, Beijing, China.
Peking University First Hospital · CNBeijing Chest Hospital · CNChinese Academy of Sciences · CNPeking University · CNBeijing Institute of Genomics · CNShenyang Anorectal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Whole-exon sequencing (WES) is a commercially available tool for hereditary disease testing. However, little is known about hereditary upper-tract urothelial carcinoma (UTUC) in the Chinese population. This study aims to investigate the prevalence of Lynch syndrome (LS) in UTUC patients with high-risk features and identify the germline mutations of genetic predisposition gene mutations in those patients. Methods: In total, 354 consecutive UTUC patients undergoing surgery were universally recruited, of whom 108 patients under 60 years old or with a personal/family history of cancer underwent universal immunohistochemistry staining to detect the expression of mismatch repair (MMR) proteins (MLH1, MSH2, MSH6 and PMS2). Patients with deficient or weak MMR protein staining or meeting the Amsterdam II criterion were defined as suspected LS patients, who further experienced microsatellite instability (MSI) (BAT25, BAT26, BAT40, D2S123, D5S346, D17S250) detection and performed WES analysis to explore germline pathogenic/likely pathogenic (P/LP) alterations. Results: Of 108 patients, 90 (83.3%) cases were included due to younger than 60 years, and 18 cases due to personal/family history. IHC staining identified 21 patients with deficient MMR protein staining and 15 cases with weak MMR protein staining. Three cases met the Amsterdam II criterion but with proficient MMR protein staining. Finally, WES analysis was performed in 38 suspected LS patients and P/LP germline mutations were identified in 22 individuals. Genetic testing confirmed 5 LS cases, including 3 cases with novel mutations. MSI-harboring tumor was discovered in 4 LS cases, one of whom had weak MMR protein staining. Germline P/LP variants in DNA damage repair genes were found in 11 cases. In addition, we found that 11 patients had high- or moderate- penetrance P/LP mutations other than MMR genes. The common P/LP variants in high- or moderate-penetrance genes were 4 in ATM, 3 in MSH6 and KIT, and 2 in APC, NF1 and DICER. Conclusions: We identified approximately 11% of UTUC cases as suspected LS and at least 1.4% patients with confirmed LS-associated UTUC. In addition, broader germline genetic testing could be considered to screen for cancer severity in hereditary UTUC patients.

Indexed as

DNA mismatch repairinherited cancerLynch syndromeupper tract urothelial carcinomawhole-exon sequence

Identifiers

PMID35372080
PMCPMC8966221
OpenAlexW4221061427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.